

Drug Monograph

Drug/Drug **Levothyroxine (levothyroxine sodium) Injection/**
Class: **Thyroid Hormone Replacement Agent**
Prepared for: MO HealthNet
Prepared by: ACS, A Xerox Company

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each vial of levothyroxine sodium 100 mcg contains 20 mcg/mL of levothyroxine sodium when reconstituted to 5 mL.

Manufacturer: APP Pharmaceuticals, LLC, Schaumburg, IL 60173

Indications: Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma.

Costs: \$55.00 per vial of levothyroxine sodium 100 mcg.

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications PA Not Required

Prepared By: Katie Wilbers, Pharm.D.
Date: February 9, 2012